Recursion Pharmaceuticals, Inc. $RXRX Shares Acquired by Profund Advisors LLC

Profund Advisors LLC lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 120.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 356,662 shares of the company’s stock after acquiring an additional 195,207 shares during the period. Profund Advisors LLC owned 0.07% of Recursion Pharmaceuticals worth $1,459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RXRX. ARK Investment Management LLC raised its position in Recursion Pharmaceuticals by 1.7% during the 3rd quarter. ARK Investment Management LLC now owns 33,545,499 shares of the company’s stock worth $163,702,000 after buying an additional 556,868 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 10.3% in the 3rd quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock valued at $194,127,000 after acquiring an additional 3,708,975 shares during the last quarter. Rafferty Asset Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 110.6% in the 3rd quarter. Rafferty Asset Management LLC now owns 750,191 shares of the company’s stock valued at $3,661,000 after acquiring an additional 394,022 shares during the last quarter. DNB Asset Management AS acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter worth $1,531,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Recursion Pharmaceuticals by 94.8% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 1,774,995 shares of the company’s stock worth $8,662,000 after purchasing an additional 863,910 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Up 3.9%

Shares of Recursion Pharmaceuticals stock opened at $2.96 on Thursday. The firm has a 50-day simple moving average of $3.30 and a two-hundred day simple moving average of $3.93. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $2.77 and a fifty-two week high of $7.18. The company has a market cap of $1.57 billion, a P/E ratio of -2.47 and a beta of 1.05.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. The firm had revenue of $6.47 million for the quarter, compared to analysts’ expectations of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The company’s quarterly revenue was down 56.8% on a year-over-year basis. During the same period last year, the firm earned ($0.50) EPS. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. lowered their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Bank of America reduced their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Finally, Morgan Stanley lifted their price target on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $8.10.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Ben R. Taylor sold 7,956 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $3.39, for a total value of $26,970.84. Following the sale, the chief financial officer directly owned 1,180,318 shares of the company’s stock, valued at approximately $4,001,278.02. This trade represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $3.52, for a total value of $105,600.00. Following the transaction, the director directly owned 6,199,863 shares of the company’s stock, valued at approximately $21,823,517.76. The trade was a 0.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 96,254 shares of company stock valued at $320,369. Company insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.